<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01744756</url>
  </required_header>
  <id_info>
    <org_study_id>pterygium bevacizumab</org_study_id>
    <nct_id>NCT01744756</nct_id>
  </id_info>
  <brief_title>Subconjunctival Bevacizumab and Recurrent Pterygium</brief_title>
  <acronym>BRP</acronym>
  <official_title>Interventional Trial of Subconjunctival Bevacizumab in Recurrent Pterygium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Olhos de Goiania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Olhos de Goiania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to research whether subconjunctival bevacizumab injection may potentially suppress
      neovascularization in pterygium, retarding and decreasing the size of recurrent pterygium.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Pacients with recurrent pterygium

        2. Anti-VEGF therapy -Bevacizumab
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pterygium size after subconjunctival bevacizumab</measure>
    <time_frame>8 weeks</time_frame>
    <description>-Size of recurrent pterygium (measured in mm) after injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>8 weeks</time_frame>
    <description>-Number of patients with hyposphagma and irritative symptoms after subconjunctival injection</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Recurrent Pterygium</condition>
  <arm_group>
    <arm_group_label>Subconjunctival Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One aplication of subconjunctival Bevacizumab 0,5 ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>One subconjunctival aplication of Bevacizumabe 0,5ml</description>
    <arm_group_label>Subconjunctival Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recurrent pterygium

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  History of myocardial infarction

          -  History of stroke
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Larissa S Stival, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto de Olhos de Goiania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto de Olhos de Goiania</name>
      <address>
        <city>Goiania</city>
        <state>Goias</state>
        <zip>74110120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2012</study_first_submitted>
  <study_first_submitted_qc>December 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2012</study_first_posted>
  <last_update_submitted>December 6, 2012</last_update_submitted>
  <last_update_submitted_qc>December 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Subconjunctival Bevacizumab</keyword>
  <keyword>Recurrent pterygium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pterygium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

